SCHEMBL3497703

SCHEMBL3497703

CC1CC2(CCCN(C(=O)OC(C)(C)C)C2)C(=O)N1CC1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.40
HRH3 Q9Y5N1 4/20 0.39
KDM1A O60341 2/20 0.39
USP30 Q70CQ3 1/20 0.38
HPGD P15428 1/20 0.37
FEN1 P39748 1/20 0.37
CTSD P07339 1/20 0.36
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
THRB P10828 1/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
NR1H2 P55055 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 1/20 0.35
FPR3 P25089 1/20 0.34
FPR2 P25090 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498100 0.88 USP30 (0.39) BACE1HRH3KDM1AUSP30HPGD
SCHEMBL14221991 0.87 USP30 (0.39) BACE1HRH3KDM1AUSP30HPGD
SCHEMBL14222817 0.85 GRIN2B (0.39) BACE1HRH3KDM1AUSP30HPGD
SCHEMBL3498132 0.84 MAPT (0.41) HRH3KDM1AUSP30HPGDMAPT
SCHEMBL3497973 0.84 USP30 (0.37) BACE1HRH3KDM1AUSP30HPGD
SCHEMBL3497446 0.84 USP30 (0.39) BACE1HRH3KDM1AUSP30HPGD
SCHEMBL3497614 0.82 USP30 (0.36) BACE1HRH3KDM1AUSP30HPGD
SCHEMBL14222282 0.82 USP30 (0.38) BACE1HRH3KDM1AUSP30HPGD
SCHEMBL3497370 0.81 USP30 (0.45) BACE1HRH3KDM1AUSP30DDB1
SCHEMBL3495850 0.81 HPGD (0.38) BACE1HRH3KDM1AUSP30HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC BACE1 2047/4885HRH3 4836/4885KDM1A 2889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.